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Abstract: Aims: We aimed to observe the effects of apelin supplementation on the plasma levels of nesfatin-1 
in DOCA-salt hypertensive and normal rats. 
Methods: For this purpose, 28 young Wistar albino male rats were divided into four groups; Control (C), Control 
+ Apelin (C+A), Hypertension (HT) and Hypertension + Apelin (HT+A). Hypertension was induced by injection 
of DOCA-salt (25 mg/kg, s.c.) twice weekly, 4 weeks, whereas intraperitoneal apelin was administered (200 
μg.kg-1) for 17 days. Plasma nesfatin-1 and apelin levels were measured with ELISA. Systolic blood pressure 
was monitored using a tail cuff system. The relationships between plasma nesfatin levels and blood pressure 
were assessed.
Results: Plasma nesfatin-1 levels was found lower in control animals compared to C+A, HT and HT+A groups (p = 
0.002, p = 0.026 and p = 0.011, respectively). Systolic blood pressures were similar in the C and C+A groups, but 
systolic blood pressures of the HT and HT+A groups was found signifi cantly higher than the C and C+A groups.
Conclusions: In conclusion, apelin administration induced an increment of nesfatin-1 in normal rats and plasma 
levels of nesfatin-1 increase in DOCA-salt hypertension rats. But apelin addition in hypertension did not cause 
an extra increase in nesfatin-1 levels. This is the fi rst report to investigate the effect of apelin administration on 
plasma nesfatin levels of normal and hypertensive rats (Fig. 2, Ref. 44). Text in PDF www.elis.sk.
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Introduction
Hypertension, occuring due to many genetic and environ-
mental factors, is a complex and multi factorial disease (1). Many 
pathophysiological factors such as increase in sympathetic ner-
vous system activity, overproduction of vasoconstrictors such as 
endothelin and thromboxane, overproduction of sodium retaining 
hormones, insuffi cient intake of potassium and calcium, increased 
and inappropriate renin secretion, defi ciency of vasodilators such 
as prostaglandins and nitric oxide, congenital abnormalities of 
resistance vessels, diabetes mellitus, insulin resistance, obesity, 
increased activity of vascular growth factors and changes of cel-
lular ion transport play a role in the formation of hypertension (2).
Apelin was fi rstly isolated from bovine stomach by Tatemoto et 
al in 1998 (3). Apelin, secreted and produced by mature adipocyte, 
is described as a new adipocytokines (4). The peptide, expressed 
in human and rat various tissues including heart, lungs, testes, 
ovary, mammary glands, brain, liver, skeletal muscle, kidney and 
plasma (5, 6), has been identifi ed as the endogenous ligand of the 
G-protein-coupled receptor APJ (3). The apelin gene encodes a 
pre-proprotein of 77 amino acids with a signal peptidein the N-ter-
minal region. The pre-proprotein was fragmented in endoplasmic 
reticulum to compose of a pro-protein of 55 amino acid (3). Four 
active isoforms as apelin-12, 13, 17 and 36, each showing different 
receptor binding affi nities, were produced from prepropeptide (7). 
It’s thought to be that the 13 amino acid in the C terminal region of 
the pro-protein is responsible for biological activity of the peptide 
(8). Increasing evidence suggests that apelin regulates multiple 
physiological functions, including food intake, cell proliferation, 
regulation of blood pressure and vascular tonus, glucose utiliza-
tion, angiogenesis and fl uid homeostasis. Therefore reported that 
is multifunctional neuropeptide to play role in diabetes, obesity, 
hypertension and cardiovascular diseases (9, 10). 
Nesfatin-1 is a newly discovered by Oh-I et al in 2006 (11). 
Nesfatin-1, 82-amino-terminal fragment derived from larger 
protein NUCB2 (nonesterifi ed fatty acid/nucleobinding 2), is very 
high amino acid sequence homology among rat, mouse, and human 
species (> 85 %) (12). NUCB2 is at times referred to as NEFA/
NUCB2 but in this case it is likely that NEFA is defi ned as “DNA 
binding/EF hand/acid amino acid region” (13). NUCB2 has many 
regions for posttranslational modifi cation. Structural analyses re-
vealed the presence of several conserved cleavage recognition sites 
for prohormone convertases (PC3/1 and PC2) within rat NUCB2/
nesfatin sequence, thus suggesting this to be a precursor that gives 
rise, by differential proteolytic processing, to several active pep-
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tides. The predicted (major) fragments of such processing were 
termed nesfatin-1, nesfatin-2, and nesfatin-3 (14, 15). Nesfatin-2 
and nesfatin-3, the fragments of NUCB2, have the same structure 
as the DNA structure of calcium binding proteins However, there 
is no information about the biological activity of these peptides 
(14, 16, 17, 18). In particular, nesfatin-1 seems to be released by 
the concerted actions of PC3/1 and PC2. Functional analyses of 
three potential fragments of nesfatin-1 molecule (namely, the N-
terminal (N23), the C-terminal (C29), and the central (M30) frag-
ments) revealed that the mid-fragment contains the active site for 
the anorectic effects of nesfatin-1 (15, 19). It’s reported that nes-
fatin-1 is a peptide secreted in the tissues of central and peripheral 
nervous system and involved in the regulation of homeostasis. 
Nesfatin1 is able to cross the blood brain barrier in both the blood-
to-brain and brain-to-blood directions (20, 21) and was discovered 
a hypothalamus secreted protein that conduces to a decrease on 
food and water intake and to an increase on energetic waste (22). 
Recently studies have been shown an increasing blood pressure 
with administration of nesfatin-1. It has also been shown to play 
an important roles in the control of cardiovascular function (23, 
24). However, the effect mechanism of nesfatin-1 on the blood 
pressure is not clear.
Although these peptides, apelin and nesfatin-1, were expressed 
various tissues and organs, the physiological effects of them were 
not fully elucidated. Apelin and nesfatin-1 are multifunctional 
peptides that have been studied in similar disease or physiologic 
states that there may be a relationship between these two peptides. 
Recently studies have been suggested that apelin can be used as a 
therapeutic and protective agent on diseases as hypertension and 
type II diabetes in the future. For that reason, we aimed to inves-
tigate the effects of the apelin administration on the blood levels 
of nesfatin-1 and blood pressure in DOCA-salt hypertensive and 
normal rats.
Materials and methods
Animals and study design
Twenty-eight Wistar Albino 8–10 week old male rats (180–300 g)
were housed in the Experimental Research Unit of the Univer-
sity of Pamukkale, Denizli, Turkey. They were reared under the 
supervision of a veterinarian, kept in a well-ventilated, noiseless 
environment, and allowed free access to food and water. They 
were housed in plastic cages (42 x 26 x 15 cm), each containing 
three to four rats, under standard laboratory conditions (ambient 
temperature of 22 ± 1 °C, 12 hour light-dark cycle). The study 
was approved by the Pamukkale University Ethics Committee for 
Experimental Animals.
Rats were randomly divided into four groups; control group 
(C) (n = 7), control + apelin group (C+A) (n = 7), DOCA-salt hy-
pertensive groups (HT) (n = 7), DOCA-salt hypertensive group + 
apelin (HT+A) (n = 7). The body weights of rats were measured 
at the beginning and at the end of the experiment.
Hypertension modeling
Hypertension was induced by DOCA-salt treatment as pre-
viously described (25). DOCA was injected (25 mg/kg of body 
weight in 0.4 ml of dimethylformamide subcutaneously), twice 
weekly for 4 weeks, and tap water for drinking was replaced by 1 
% NaCl during the treatment period. In the control groups, the same 
volume of serum physiologic was injected. The rats of C+A and 
HT+A groups were treated with pyroglutamylated apelin-13 (Pyr-
AP13; 200 μg.kg-1.day-1 ip) during 17 days (26). Apelin adminis-
tration initiated in HT+A group after than hypertension developed.
Blood pressure monitoring
Systolic blood pressure was measured in awake rats using a 
non-invasive tail cuff blood pressure measuring system (Power 
Fig. 1. Systolic blood pressure of all groups. * − shows signifi cance be-
tween control group and HT and HT+A groups (p < 0.01), † − shows 
signifi cance between C+A group and HT and HT+A groups (p < 0.01), 
¥ − shows signifi cance between HT and HT+A group (p < 0.01).
Fig. 2. The plasma levels of nesfatin in groups. * − shows signifi cance 
between the control group and C+A, HT and HT+A (* p < 0.01, ** 
p < 0.05). 
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Lab/8SP data acquisition system, ADInstruments Co.) before 
DOCA treatment and on the 14th, 21th, 28th days of DOCA treat-
ment. Blood pressure of rats treated with DOCA started to rise 
after one week and reached high systolic values (≥ 160 mmHg) 
after four weeks. Rats were placed in a plastic restrainer (Kursun-
luoglu Metal Co., Denizli, Turkey). All measurements were per-
formed without anesthesia at room temperature in a silent room. 
The physiological data was analyzed using the LabChart 6.1 Pro 
software (AD Instruments Co.) (27). 
Blood samples and measurements
At the end of the experimental period, all of the animals were 
anesthetized with Ketamin/Xylazine HCl (75 mg/kg/10 mg/kg in-
traperitoneally). Blood was collected in heparinezed tubes. After 
centrifugation, plasma was stored at −80 °C until analysis. Plasma 
concentration of nesfatin-1 was analyzed with rat ELISA assay kit 
using the chemiluminescence method (Diagnostic Product Cor-
poration, USA) by an ELISA microplate reader (das, Digital and 
Analog Systems, Italy).
Statistical analysis
Statistical analysis was done with the SPSS (Statistical Package 
for Social Sciences) 16.0 pocket program. Results were expressed 
as the means ± standard deviation (M±SD). The Mann–Whitney 
U test was used for statistics, with p values ≤ 0.05 accepted as 
statistically signifi cant. 
Results
The effects of apelin administration in healthy and hyperten-
sive rats investigated in this study, the plasma levels of nesfatin 
and blood pressure were compared between groups. Systolic blood 
pressure (SBP) measured at the end of the study in HT and HT+A 
groups were found signifi cantly higher than C and C+A groups (p 
< 0.01) (Fig. 1). In HT+A group, SBP was observed signifi cantly 
lower than HT group (p = 0.001) (Fig. 1). The nesfatin plasma 
levels of HT, HT+A and C+A groups were found signifi cantly 
increase compared to control group (p < 0.05, p < 0.05, p < 0.01, 
respectively), shown in Figure 2. 
Discussion
Hypertension can occur in many genetic and environmental 
factors and is a complex, multifactorial and major health problem 
(1). Acute positive inotropic effects of apelin have been shown in 
both healthy and heart failure rats (28, 29). Apelin have been re-
ported as a marker of heart failure (28) and the vasodilatory effects 
of apelin have been shown in various studies (30, 31). However, 
it is worthwhile to keep it in mind that the reports on apelin’s ef-
fects on blood pressure (BP) are varied. While there are studies, 
which showed decreased arterial pressure via a nitric oxide (NO)-
dependent mechanism (32, 33, 34), there were reports showing 
an increased arterial pressure (33), biphasic change of mean arte-
rial blood pressure (32), and lack of BP change following apelin 
administration (35). Dose, method of administration, experimen-
tal subject, could contribute to this variation. It is suggested that 
apelin, reported the effects on cardiovascular regulation, can be a 
potential therapeutic target in hypertension (36). Nesfatin-1, se-
creted in hypothalamus and brain stem, has been reported to be a 
peptide effi cacy in the control of appetite (anorexigenic effects) 
regardless of leptin pathway (16, 11). There is a limited study about 
the effects of nesfatin-1 on blood pressure. The previous studies 
reported that nesfatin-1 can increase the mean arterial blood pres-
sure in rats (25) and modulates blood pressure through directly 
acting on peripheral arterial resistance (23). 
In the present study, we examined the effects of intraperito-
neally injected apelin on plasma nesfatin levels and relationship 
between blood pressure and nesfatin-1 in normal hypertensive 
rats. The major fi nding of this study is that apelin administration 
increase plasma nesfatin-1 levels in normal rats. We cannot discuss 
a potential mechanism of how apelin might regulate nesfatin-1. 
Because this is the fi rst report on the effect of apelin administra-
tion on plasma nesfatin-1 levels in normal rats. On the other hand, 
systolic blood pressure has not changed. We did not fi nd a previous 
research about effect of apelin administration on plasma nesfatin 
levels. Maternal serum and cord blood apelin and nesfatin-1 con-
centrations in pregnant women with and without gestational dia-
betes mellitus (GDM) were investigated by Aslan et al (38). They 
reports increased apelin decreased nesfatin-1 levels in pregnant 
women with GDM compared to healthy pregnant women. How-
ever, a signifi cant correlation was not found between the levels 
of nesfatin and Apelin (38). In addition, the correlation between 
apelin and nesfatin-1 levels in breast milk of lactating women and 
maternal serum were investigated in a study performed by Aydin 
et al They did not report signifi cantly relationship (39). 
In the current study, the plasma levels of nesfatin in hyper-
tension group signifi cantly increased compared to normal rats. 
In recent studies, increasing blood pressure effect of nesfatin-1 
has been demonstrated (14, 24, 22). Yosten et al reported that in-
tracerebroventricular injection of nesfatin 1 caused an increased 
blood pressure in rats (24). The hypertensive effect of nesfatin-1 
is thought to be mediated via the activation of sympathetic nerves 
through acting on melanocortin-3/4 receptors. It was further shown 
that the hypertensive effect of nesfatin-1 was mediated via act-
ing on hypothalamus oxytocin receptor, which is thought to be 
downstream of the melanocortin system (22). It is well known 
that sodium nitroprusside (SNP) (NO) induces smooth muscle 
relaxations via producing cGMP. Recently, study reported that 
nesfatin-1 affected rat isolated mesenteric artery and specifi cally 
impaired the SNP-induced smooth muscle relaxations through 
the inhibition of cGMP production (23). It is not mentioned by 
nesfatin administration in the current study. On the contrary, the 
increased plasma concentration of nesfatin was observed in hy-
pertensive rats developed with DOCA-salt hypertension models. 
The DOCA-salt model including low-renin form of hypertension 
is similar to other experimental models that depend on high salt 
intake and reduced renal mass leading to hypervolemia. Increased 
ET-1 was shown both in vessel and in different tissues (39, 40). It 
is reported that excess vasoconstrictor substances such as Ang II 
and ET-1 or vasodilatation as a result of the formation of deletion 
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of genes encoding G protein-coupled receptors played an impor-
tant role in the maintenance of hypertension (41). However, the 
release of aldosterone, antidiuretic hormone synthesis, sympathetic 
activation and salt absorption from renal tubules leads to the de-
velopment of hypertension (42). We did not found any study on 
the relationship between nesfatin and ANG II, ET1, aldosterone, 
antidiuretic hormone. In this study, an increased plasma nesfatine-1 
concentration was probably due to an increased ET-1 as well as it 
could be increased independent of ET-1. It was fi rst demonstrated 
that intraperitoneal apelin injection in healthy animals increased 
the plasma levels of nesfatin-1, but this high level of endogen 
nesfatin-1 did not affect the blood pressure. On the contrary, pre-
vious studies reported that exogen nesfatin administration, giving 
intracerebraventricular (43) and intravenous (23) caused a high 
blood pressure. The results of the current study demonstrated 
that apelin treatment resulted in an increment nesfatin-1 levels in 
DOCA-salt hypertansive+apelin rats compared to control animals. 
The previous research indicated that the addition of intracerabral 
nesfatin induced hypertension (43) and intravenous administra-
tion of nesfatin-1 increased vascular contraction by inhibiting 
NO production (23) Also the low blood pressure was observed 
in HT+A compared to HT group despite the same nesfatin level 
shown in these groups. The reason for this situation could be apelin 
administration. Because in our previous study we demonstrated 
that addition of apelin reduces blood pressure in DOCA-salt rats 
(44). There are no studies reported in literature for plasma levels 
nesfatin in hypertension. In this sense, this study is the fi rst study 
on plasma levels of nesfatin in experimental hypertension.  
As a result, according to our fi ndings, apelin administration 
increased nesfatin-1 blood level in normal rats, and there was an 
increased nesfatin-1 level in the hypertensive rats with or without 
administration of apelin. However, we can say this increment is 
not suffi cient to increase the blood pressure. The fi rst report on 
the effect of apelin administration on plasma nesfatin-1 levels in 
normal and DOCA-salt hypertensive rats. Apelin considered to be 
used for the prevention and treatment in hypertension that reason 
further detailed studies are needed to explain the relationship be-
tween apelin and nesfatin.
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